文献速递淋巴瘤

R-GemOx治疗复发或难治性弥漫大B细胞淋巴瘤的结局:一项多中心队列研究

Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With R-GemOx: A Multicenter Cohort Study.
PubMed 文献 · Am J Hematol · 2025-02-07

这项来自美国八家学术中心的多中心回顾性队列研究纳入183例复发或难治性弥漫大B细胞淋巴瘤及高级别B细胞淋巴瘤患者,评估R-GemOx方案的疗效。全部患者总缓解率为45%,完全缓解率为29%,中位无事件生存期为2.3个月,中位总生存期为13.5个月。

要点

  • 全部R-GemOx治疗患者ORR为45%,CR率为29%,中位EFS为2.3个月,中位OS为13.5个月。
  • 无ASCT或CAR-T巩固意图者ORR为33%、CR率为18%,中位EFS为2.0个月,中位OS为9.5个月。
  • 以R-GemOx桥接ASCT或CAR-T者ORR为57%、CR率为36%,中位EFS为3.5个月,中位OS为17.4个月。

核心结论

  • 这些数据为快速演变中的复发或难治性弥漫大B细胞淋巴瘤治疗格局提供了R-GemOx的基准。

研究设计与样本

  • 多中心回顾性研究,来自美国八家学术中心的LEO CReWE队列,纳入183例接受R-GemOx治疗的复发或难治性弥漫大B细胞淋巴瘤及高级别B细胞淋巴瘤患者。
  • 亚组包括无ASCT或CAR-T巩固意图者(n=100)、以R-GemOx桥接ASCT或CAR-T者(n=83)以及年龄70岁及以上者(n=71)。

主要发现

  • 全部R-GemOx治疗患者的总缓解率为45%,完全缓解率为29%,中位无事件生存期为2.3个月,中位总生存期为13.5个月。
  • 无ASCT或CAR-T巩固意图者总缓解率为33%,完全缓解率为18%,中位无事件生存期为2.0个月,中位总生存期为9.5个月。
  • 以R-GemOx桥接ASCT或CAR-T者总缓解率为57%,完全缓解率为36%,中位无事件生存期为3.5个月,中位总生存期为17.4个月。
  • 年龄70岁及以上者总缓解率为53%,完全缓解率为33%,中位无事件生存期为2.2个月,中位总生存期为13.9个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rituximab, gemcitabine, and oxaliplatin (R-GemOx) is a commonly used chemoimmunotherapy regimen for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), but there are limited real-world data. In a multicenter retrospective study from a cohort of eight US academic centers (LEO CReWE), we evaluated 183 patients with R/R DLBCL and high-grade B cell lymphoma treated with R-GemOx, including subgroups treated without intent for consolidation with autologous stem cell transplant (ASCT) or chimeric antigen receptor (CAR) T cell therapy (n = 100), those utilizing R-GemOx as a bridge to ASCT or CAR T (n = 83), and those aged 70 and older (n = 71). Overall response rates (ORRs) for all patients treated with R-GemOx were 45% with a complete response (CR) rate of 29%. The median event-free survival (EFS) was 2.3 months, and the median overall survival (OS) was 13.5 months. Patients receiving R-GemOx without intent for ASCT or CAR T had ORR and CR rates of 33% and 18%, respectively, with median EFS and OS of 2.0 and 9.5 months, respectively. Patients receiving R-GemOx as a bridge to ASCT or CAR T had ORR and CR rates of 57% and 36%, respectively, with median EFS and OS of 3.5 and 17.4 months, respectively. Patients receiving R-GemOx aged 70 and older had ORR and CR rates of 53% and 33%, respectively, with median EFS and OS of 2.2 and 13.9 months, respectively. These data provide a benchmark for R-GemOx in the rapidly evolving landscape of R/R DLBCL therapies.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Yamshon S, Koff JL, Larson MC, et al. Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With R-GemOx: A Multicenter Cohort Study. Am J Hematol. 2025. PMID: 39918101. doi:10.1002/ajh.27630

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。